
  
    
      
        Introduction_NNP
        Breast_NNP cancer_NN is_VBZ the_DT leading_VBG female_JJ malignancy_NN in_IN the_DT
        world_NN and_CC is_VBZ now_RB the_DT most_RBS common_JJ cancer_NN in_IN Nigeria_NNP [_NN 1_CD 2_CD 3_CD
        ]_NN ._. Despite_IN this_DT ,_, there_EX is_VBZ a_DT sixfold_JJ variation_NN in_IN incidence_NN
        when_WRB Western_JJ countries_NNS are_VBP compared_VBN with_IN the_DT developing_VBG
        countries_NNS of_IN Africa_NNP and_CC Asia_NNP ,_, and_CC immigrants_NNS from_IN low_JJ
        incidence_NN countries_NNS tend_VBP to_TO acquire_VB the_DT rate_NN of_IN their_PRP$ new_JJ
        environments_NNS [_NN 2_CD 4_CD ]_NN ._. Some_DT of_IN this_DT variation_NN may_MD be_VB due_JJ to_TO
        demographic_JJ factors_NNS such_JJ as_IN longer_JJR life_NN expectancy_NN ,_, better_JJR
        reporting_NN of_IN disease_NN and_CC improved_VBN access_NN to_TO clinical_JJ care_NN ._.
        There_EX is_VBZ increasing_VBG interest_NN ,_, however_RB ,_, in_IN the_DT relative_JJ
        importance_NN of_IN environmental_JJ and_CC genetic_JJ factors_NNS as_IN
        explanations_NNS for_IN this_DT difference_NN ._.
        In_IN general_JJ ,_, African_JJ breast_NN cancer_NN patients_NNS tend_VBP to_TO
        present_VB at_IN a_DT young_JJ age_NN ,_, with_IN large_JJ tumors_NNS and_CC multiple_JJ
        nodal_NN involvements_NNS ,_, and_CC have_VBP poorer_RBR clinical_JJ and_CC
        pathological_JJ prognostic_JJ factors_NNS compared_VBN with_IN Caucasian_NNP
        patients_NNS ._. These_DT characteristics_NNS are_VBP somewhat_RB similar_JJ to_TO
        that_DT of_IN African-_NNP Americans_NNPS but_CC are_VBP in_IN contrast_NN with_IN those_DT of_IN
        non-_NN Hispanic_NNP Whites_NNP in_IN the_DT USA_NNP ,_, thus_RB heightening_VBG the_DT
        interest_NN in_IN the_DT role_NN of_IN genetic_JJ factors_NNS in_IN the_DT etiology_NN of_IN
        breast_NN cancer_NN in_IN general_JJ ,_, and_CC in_IN people_NNS of_IN African_JJ origin_NN
        in_IN particular_JJ [_NN 3_CD 5_CD ]_NN ._.
        One_CD of_IN the_DT often_RB cited_VBN reasons_NNS for_IN the_DT difference_NN in_IN
        breast_NN cancer_NN incidence_NN in_IN Africa_NNP compared_VBD with_IN Western_JJ
        countries_NNS is_VBZ the_DT difference_NN in_IN environmental_JJ risk_NN factors_NNS
        such_JJ as_IN diet_NN and_CC physical_JJ activity_NN (_( both_DT contributing_VBG to_TO
        obesity_NN )_) ,_, use_NN of_IN hormones_NNS /_NN other_JJ medications_NNS ,_, and_CC
        obstetric_JJ /_NN gynecological_JJ practices_NNS [_NN 6_CD ]_NN ._. In_IN the_DT current_JJ
        paper_NN ,_, we_PRP present_VB the_DT results_NNS of_IN the_DT first_JJ study_NN of_IN the_DT
        association_NN between_IN waist-hip_JJ ratio_NN (_( WHR_NNP )_) and_CC breast_NN cancer_NN
        in_IN an_DT indigenous_JJ African_JJ population_NN ._.
        The_DT WHR_NNP has_VBZ emerged_VBN as_IN an_DT important_JJ metameter_NN of_IN the_DT
        association_NN between_IN central_JJ adiposity_NN and_CC many_JJ
        obesity-related_JJ diseases_NNS ._. Positive_JJ correlations_NNS have_VBP been_VBN
        seen_VBN with_IN coronary_JJ heart_NN disease_NN ,_, adult-onset_JJ diabetes_NN
        mellitus_JJ and_CC stroke_NN [_NN 7_CD ]_NN ._. However_RB ,_, the_DT result_NN with_IN breast_NN
        cancer_NN has_VBZ been_VBN inconsistent_JJ [_NN 8_CD ]_NN ._. Abdominal_NNP obesity_NN may_MD
        be_VB related_VBN to_TO breast_NN cancer_NN through_IN aberrant_NN insulin_NN
        signaling_VBG leading_VBG to_TO increased_VB endogenous_JJ androgen_NN and_CC
        estrogen_NN levels_NNS [_NN 9_CD ]_NN ._.
      
      
        Methods_NNP
        
          Case_NN ascertainment_NN
          All_DT consecutive_JJ cases_NNS of_IN breast_NN cancer_NN ,_, regardless_RB of_IN
          previous_JJ history_NN ,_, seen_VBN at_IN presentation_NN and_CC later_RB
          confirmed_VBD histologically_RB in_IN the_DT Departments_NNP of_IN Surgery_NNP
          and_CC Radiotherapy_NNP of_IN the_DT University_NNP College_NNP Hospital_NNP ,_,
          Ibadan_NNP ,_, Nigeria_NNP ,_, from_IN March_NNP 1998_CD to_TO August_NNP 2000_CD were_VBD
          recruited_VBN at_IN their_PRP$ first_JJ clinic_NN presentation_NN ,_, after_IN
          obtaining_VBG informed_VBN consent_NN ._. Nurse_NNP interviewers_NNS asked_VBD them_PRP
          which_WDT risk_VBP factors_NNS did_VBD apply_VB at_IN the_DT time_NN when_WRB they_PRP were_VBD
          last_VBP well_RB ._. The_DT interviewer_NN then_RB measured_VBD the_DT height_NN ,_,
          weight_NN ,_, and_CC hip_NN circumference_NN at_IN its_PRP$ widest_JJS diameter_NN ._.
          Waist_NNP circumference_NN was_VBD measured_VBN according_VBG to_TO the_DT
          guidelines_NNS in_IN the_DT World_NNP Health_NNP Organization_NNP MONICA_NNP
          Project_NNP manual_JJ [_NN 10_CD ]_NN ._.
          There_EX were_VBD 312_CD cases_NNS ,_, of_IN which_WDT 73_CD indicated_VBD that_IN they_PRP
          had_VBD lived_VBN predominantly_RB in_IN a_DT rural_JJ area_NN and_CC were_VBD
          excluded_VBN ._. There_EX were_VBD five_CD refusals_NNS and_CC no_DT further_JJ
          information_NN was_VBD available_JJ from_IN these_DT ,_, leaving_VBG 234_CD
          cases_NNS ._.
        
        
          Control_NN ascertainment_NN
          During_IN the_DT period_NN of_IN case_NN recruitment_NN ,_, a_DT community_NN
          adjoining_JJ the_DT hospital_NN was_VBD randomly_RB selected_VBN by_IN ballot_NN
          based_VBN on_IN comparability_NN with_IN the_DT hypothetical_JJ catchment_NN
          area_NN of_IN the_DT hospital_NN ._. Community_NN consent_NN was_VBD sought_VBN from_IN
          the_DT Chief-in-_NNP Council_NNP and_CC approval_NN for_IN the_DT study_NN was_VBD
          communicated_VBN to_TO members_NNS of_IN the_DT community_NN through_IN heads_NNS of_IN
          households_NNS ._. The_DT census_NN register_NN of_IN the_DT people_NNS living_VBG in_IN
          the_DT community_NN was_VBD obtained_VBN and_CC community_NN consent_NN sought_VBN
          for_IN the_DT study_NN ._. Names_NNS were_VBD then_RB randomly_RB selected_VBN from_IN the_DT
          community_NN register_NN and_CC the_DT people_NNS were_VBD invited_VBN to_TO visit_VB a_DT
          clinic_NN set_VBN up_RP in_IN the_DT community_NN for_IN the_DT study_NN ._.
          Inclusion_NNP criteria_NNS for_IN the_DT controls_NNS were_VBD females_NNS aged_VBN
          older_JJR than_IN 18_CD years_NNS ,_, absence_NN of_IN any_DT type_NN of_IN cancer_NN at_IN
          recruitment_NN ,_, predominant_NN urban_JJ residence_NN for_IN most_JJS of_IN
          their_PRP$ lives_NNS and_CC the_DT ability_NN to_TO give_VB informed_VBN consent_NN ._. No_DT
          matching_NN of_IN controls_NNS to_TO cases_NNS was_VBD performed_VBN ._. After_IN
          explaining_VBG the_DT project_NN to_TO the_DT potential_JJ participant_NN ,_, a_DT
          complete_JJ physical_JJ examination_NN was_VBD carried_VBN out_RP ._. A_DT trained_VBN
          nurse_NN then_RB interviewed_VBD the_DT participants_NNS ,_, measured_VBD their_PRP$
          height_NN ,_, their_PRP$ weight_NN ,_, their_PRP$ hip_NN circumference_NN at_IN its_PRP$
          widest_JJS diameter_NN and_CC their_PRP$ waist_NN circumference_NN 1_CD inch_NN
          below_IN the_DT navel_NN ,_, and_CC completed_VBD the_DT questionnaires_NNS ._. A_DT
          total_NN of_IN 278_CD subjects_NNS were_VBD interviewed_VBN ,_, of_IN which_WDT 273_CD were_VBD
          recruited_VBN ;_: there_EX were_VBD three_CD refusals_NNS ,_, and_CC two_CD people_NNS were_VBD
          not_RB recruited_VBN on_IN account_NN of_IN a_DT diagnosis_NN of_IN cancer_NN (_( head_NN
          of_IN the_DT pancreas_NN cancer_NN in_IN one_CD and_CC colorectal_NN cancer_NN in_IN
          the_DT other_JJ )_) ._.
        
        
          Data_NNP collection_NN and_CC analysis_NN
          The_DT information_NN obtained_VBN from_IN the_DT cases_NNS and_CC controls_NNS
          include_VBP age_NN ,_, self-reported_JJ social_JJ status_NN based_VBN on_IN family_NN
          income_NN and_CC other_JJ baseline_NN demographic_JJ information_NN ._.
          Obstetric_NNP and_CC gynecological_JJ history_NN such_JJ as_IN age_NN of_IN onset_NN
          of_IN menarche_NN ,_, menstrual_JJ cycle_NN history_NN ,_, whether_IN periods_NNS had_VBD
          usually_RB been_VBN regular_JJ ,_, age_NN at_IN onset_NN of_IN menopause_NN (_( natural_JJ
          or_CC otherwise_RB )_) and_CC history_NN of_IN previous_JJ breast_NN disease_NN ,_, as_RB
          well_RB as_IN smoking_NN ,_, drug_NN and_CC alcohol_NN use_NN history_NN ,_, were_VBD
          obtained_VBN from_IN the_DT subjects_NNS ._. Other_JJ information_NN obtained_VBN
          included_VBD first-degree_JJ family_NN history_NN of_IN breast_NN cancer_NN ,_,
          history_NN of_IN ever_RB using_VBG estrogen-containing_JJ contraceptives_NNS
          and_CC where_WRB they_PRP had_VBD lived_VBN most_JJS of_IN their_PRP$ lives_NNS (_( whether_IN in_IN
          a_DT rural_JJ or_CC urban_JJ setting_NN )_) ._. No_DT information_NN about_IN
          postmenopausal_NN hormonal_NN use_NN was_VBD obtained_VBN as_IN this_DT is_VBZ an_DT
          uncommon_JJ practice_NN in_IN Nigeria_NNP ._.
          The_DT body_NN mass_NN index_NN (_( BMI_NNP )_) (_( weight_NN [_NN kg_NN ]_NN /_NN height_NN [_NN m_NN 2_CD ]_NN ;_:
          obesity_NN =_SYM BMI_NNP ≥_NN 30_CD )_) and_CC WHR_NNP were_VBD computed_JJ (_( waist_NN
          circumference_NN [_NN cm_NN ]_NN /_NN hip_NN circumference_NN [_NN cm_NN ]_NN )_) ,_, and_CC four_CD
          subjects_NNS with_IN WHR_NNP >_NN 1_CD ._. 2_CD and_CC WHR_NNP <_NN 0_CD ._. 6_CD were_VBD
          excluded_VBN ._. The_DT rest_NN were_VBD divided_VBN into_IN tertiles_NNS and_CC treated_VBN
          as_IN categories_NNS ._. Statistical_NNP analysis_NN of_IN the_DT data_NNS was_VBD
          carried_VBN out_IN with_IN SAS_NNP version_NN 8_CD ._. 0_CD (_( SAS_NNP Institute_NNP ,_, Inc_NNP ._. ,_,
          Cary_NNP ,_, NC_NNP ,_, USA_NNP )_) separately_RB for_IN premenopausal_NN and_CC
          postmenopausal_NN women_NNS ._. Univariate_NNP analysis_NN was_VBD used_VBN to_TO
          identify_VB variables_NNS to_TO be_VB included_VBN in_IN multivariable_JJ
          analysis_NN using_VBG 
          P_NN ≤_NN 0_CD ._. 10_CD ._. Purposeful_NNP stepwise_NN
          multivariable_JJ logistic_JJ regression_NN models_NNS were_VBD built_VBN to_TO
          identify_VB statistically_RB significant_JJ variables_NNS at_IN 
          P_NN =_SYM 0_CD ._. 05_CD ,_, and_CC a_DT 10_CD %_NN or_CC greater_JJR
          change_NN in_IN the_DT β-coefficient_JJ was_VBD used_VBN to_TO identify_VB
          confounders_NNS ._. In_IN addition_NN ,_, automated_VBN stepwise_NN multivariate_NN
          logistic_JJ regression_NN models_NNS were_VBD run_VBN as_IN an_DT adjunct_NN to_TO the_DT
          aforementioned_JJ method_NN ._.
          Continuous_NNP variables_NNS were_VBD examined_VBN for_IN assumption_NN of_IN
          linearity_NN ;_: age_NN and_CC age_NN at_IN onset_NN of_IN regular_JJ menstrual_JJ
          periods_NNS were_VBD found_VBN to_TO be_VB nonlinear_NN ._. Age_NNP was_VBD subsequently_RB

          divided_VBN into_IN 5_CD -_: year_NN categories_NNS while_IN age_NN at_IN onset_NN of_IN
          regular_JJ menstrual_JJ periods_NNS was_VBD left_VBN as_IN it_PRP was_VBD because_IN the_DT
          range_NN of_IN values_NNS was_VBD narrow_JJ ,_, but_CC it_PRP was_VBD subsequently_RB
          modeled_VBN as_IN a_DT categorical_JJ variable_NN ._.
        
      
      
        Results_NNS
        
          Premenopausal_NNP women_NNS
          Tables_NNP 1_CD and_CC 2_CD present_VB the_DT results_NNS of_IN age-adjusted_JJ
          analysis_NN ._. Increasing_VBG age_NN and_CC age_NN at_IN first_JJ full-term_JJ
          pregnancy_NN were_VBD positively_RB associated_VBN with_IN risk_NN of_IN breast_NN
          cancer_NN ,_, while_IN increasing_VBG age_NN at_IN onset_NN of_IN menarche_NN was_VBD
          protective_JJ ._. Overall_RB ,_, categories_NNS of_IN WHR_NNP were_VBD not_RB
          significantly_RB associated_VBN with_IN the_DT risk_NN of_IN breast_NN cancer_NN
          but_CC there_EX was_VBD a_DT marginally_RB significant_JJ test_NN of_IN trend_NN for_IN
          a_DT positive_JJ association_NN between_IN increasing_VBG WHR_NNP and_CC breast_NN
          cancer_NN risk_NN ._. There_EX was_VBD no_DT association_NN with_IN total_JJ number_NN
          of_IN pregnancies_NNS ,_, height_NN ,_, obesity_NN (_( BMI_NNP ≥_NN 30_CD )_) weight_NN ,_, BMI_NNP ,_,
          waist_NN and_CC hip_NN circumferences_NNS ,_, family_NN history_NN of_IN breast_NN
          cancer_NN ,_, having_VBG ever_RB breastfed_JJ and_CC use_NN of_IN oral_JJ
          contraceptives_NNS ._. In_IN multivariable_JJ logistic_JJ regression_NN
          analysis_NN ,_, adjusted_VBN for_IN age_NN ,_, age_NN at_IN menarche_NN ,_, age_NN at_IN first_JJ
          pregnancy_NN and_CC height_NN ,_, there_EX was_VBD no_DT significant_JJ
          association_NN between_IN the_DT WHR_NNP and_CC breast_NN cancer_NN risk_NN (_( Table_NNP
          3_LS )_) ._.
        
        
          Postmenopausal_NNP women_NNS
          On_IN the_DT other_JJ hand_NN ,_, in_IN age-adjusted_JJ logistic_JJ regression_NN
          models_NNS among_IN postmenopausal_NN women_NNS (_( Tables_NNP 4_CD and_CC 5_LS )_) ,_,
          increasing_VBG age_NN was_VBD associated_VBN with_IN a_DT reduced_VBN breast_NN
          cancer_NN risk_NN ,_, while_IN increasing_VBG height_NN ,_, waist_NN circumference_NN
          and_CC obesity_NN (_( BMI_NNP ≥_NN 30_CD )_) were_VBD positively_RB associated_VBN with_IN
          breast_NN cancer_NN risk_NN ._. There_EX was_VBD a_DT significant_JJ association_NN
          with_IN the_DT highest_JJS tertile_NN of_IN WHR_NNP but_CC the_DT likelihood_NN ratio_NN
          test_NN (_( LRT_NNP )_) for_IN trend_NN (_( 
          P_NN =_SYM 0_CD ._. 07_CD )_) was_VBD not_RB significant_JJ ._. The_DT
          association_NN with_IN having_VBG ever_RB breastfed_JJ could_MD not_RB be_VB
          ascertained_JJ because_IN of_IN an_DT inadequate_JJ sample_NN size_NN ._. In_IN
          multivariable_JJ logistic_JJ regression_NN analysis_NN ,_, adjusted_VBN for_IN
          age_NN and_CC height_NN ,_, there_EX was_VBD a_DT significant_JJ association_NN
          between_IN the_DT highest_JJS tertile_NN of_IN WHR_NNP and_CC breast_NN cancer_NN risk_NN
          (_( LRT_NNP 
          P_NN =_SYM 0_CD ._. 10_CD ;_: Table_NNP 6_CD )_) ._.
        
      
      
        Discussion_NNP
        The_DT earliest_JJS reports_NNS of_IN the_DT positive_JJ association_NN between_IN
        energy_NN balance_NN and_CC breast_NN cancer_NN date_NN back_RB to_TO 1942_CD [_NN 11_CD ]_NN ._.
        Numerous_JJ case-control_JJ and_CC cohort_NN studies_NNS have_VBP subsequently_RB
        supported_VBN this_DT association_NN ._. However_RB ,_, the_DT strength_NN of_IN the_DT
        association_NN and_CC the_DT category_NN of_IN patients_NNS in_IN whom_WP the_DT
        association_NN was_VBD seen_VBN varied_VBD from_IN study_NN to_TO study_VB ._. In_IN
        addition_NN ,_, there_EX are_VBP methodological_JJ concerns_NNS about_IN the_DT most_RBS
        appropriate_JJ measure_NN of_IN obesity_NN ,_, and_CC which_WDT component_NN or_CC type_NN
        of_IN obesity_NN is_VBZ etiologically_RB significant_JJ ._.
        The_DT WHR_NNP ,_, a_DT measure_NN of_IN central_JJ adiposity_NN ,_, is_VBZ gaining_VBG
        increased_VBN use_NN as_IN a_DT measure_NN of_IN etiologically_RB significant_JJ
        obesity_NN and_CC is_VBZ thought_VBN to_TO be_VB more_RBR closely_RB related_VBN to_TO
        pathology_NN ,_, especially_RB coronary_JJ heart_NN disease_NN ,_, diabetes_NN
        mellitus_JJ and_CC stroke_NN [_NN 7_CD ]_NN ._. The_DT metabolic_JJ changes_NNS that_WDT
        accompany_VB obesity_NN include_VBP peripheral_JJ hyperinsulinemia_NN ,_,
        hyperglycemia_NN and_CC glucose_NN intolerance_NN ,_,
        hypertriglyceridemia_NN ,_, decreased_VBD serum_NN low-density_NN
        lipoprotein_NN ,_, increased_VBN serum_NN very_RB low-density_NN lipoprotein_NN ,_,
        increased_VBN serum_NN leptin_NN ,_, dyslipidemia_NN ,_, increased_VBN serum_NN
        cortisol_NN clearance_NN ,_, increased_VBN serum_NN C-_NNP peptide_NN level_NN ,_,
        downregulation_NN of_IN insulin_NN receptors_NNS and_CC an_DT exaggerated_JJ
        insulin_NN response_NN to_TO an_DT oral_JJ glucose_NN load_NN [_NN 12_CD 13_CD 14_CD 15_CD ]_NN ._.
        These_DT changes_NNS ,_, especially_RB when_WRB they_PRP occur_VBP in_IN early_JJ
        adulthood_NN ,_, may_MD be_VB of_IN fundamental_JJ importance_NN in_IN the_DT
        development_NN of_IN breast_NN cancer_NN [_NN 9_CD 16_CD ]_NN ._.
        Obesity_NNP is_VBZ also_RB associated_VBN with_IN significant_JJ hormonal_NN
        changes_NNS such_JJ as_IN decreased_VBN serum_NN estradiol_NN and_CC sex_NN hormone_NN
        binding_JJ globulin_NN (_( SHBG_NNP )_) levels_NNS ,_, increased_VBD peripheral_JJ fat_JJ
        conversion_NN of_IN estrogens_NNS to_TO progesterone_NN and_CC increased_VBN serum_NN
        testosterone_NN levels_NNS that_WDT may_MD be_VB associated_VBN with_IN an_DT
        increased_VBN risk_NN of_IN breast_NN cancer_NN [_NN 17_CD ]_NN ._. Estrogens_NNP are_VBP
        necessary_JJ for_IN normal_JJ breast_NN development_NN ,_, and_CC they_PRP induce_VB
        and_CC promote_VB mammary_JJ tumor_NN growth_NN in_IN animal_NN studies_NNS [_NN 18_CD ]_NN ._.
        In_IN addition_NN ,_, the_DT close_JJ association_NN between_IN increased_VBN risk_NN
        of_IN breast_NN cancer_NN and_CC certain_JJ reproductive_JJ factors_NNS such_JJ as_IN
        early_JJ menarche_NN and_CC late_JJ menopause_NN [_NN 19_CD ]_NN ,_, as_RB well_RB as_IN the_DT
        fall_NN off_RP in_IN the_DT rate_NN of_IN increase_NN in_IN the_DT incidence_NN of_IN
        disease_NN at_IN menopause_NN [_NN 20_CD ]_NN and_CC the_DT lowered_VBN risk_NN of_IN breast_NN
        cancer_NN in_IN oophorectomized_JJ women_NNS and_CC those_DT taking_VBG
        antiestrogens_NNS [_NN 21_CD 22_CD ]_NN ,_, all_DT support_NN the_DT role_NN of_IN estrogen_NN
        in_IN breast_NN carcinogenesis_NNS ._.
        The_DT results_NNS from_IN cohort_NN studies_NNS about_IN the_DT association_NN
        between_IN WHR_NNP and_CC the_DT risk_NN of_IN breast_NN cancer_NN are_VBP inconsistent_JJ ._.
        In_IN the_DT Nurses_NNP '_POS Health_NNP Study_NNP ,_, the_DT adjusted_VBN risk_NN for_IN the_DT
        highest_JJS quintile_NN compared_VBN with_IN the_DT lowest_JJS quintile_NN of_IN WHR_NNP
        among_IN postmenopausal_NN women_NNS who_WP had_VBD never_RB used_VBN hormone_NN
        replacement_NN therapy_NN was_VBD 1_CD ._. 85_CD (_( 95_CD %_NN confidence_NN interval_NN =_SYM
        1_CD ._. 25_CD -_: 2_CD ._. 74_CD )_) [_NN 23_CD ]_NN ._. Kaaks_NNP 
        et_CC al_NN ._. reported_VBD a_DT risk_NN ratio_NN of_IN 2_CD ._. 63_CD
        (_( 95_CD %_NN confidence_NN interval_NN =_SYM 1_CD ._. 09_CD -_: 6_CD ._. 35_CD )_) comparing_VBG the_DT highest_JJS
        quintile_NN with_IN the_DT lowest_JJS quintile_NN of_IN WHR_NNP [_NN 24_CD ]_NN ._. These_DT are_VBP
        similar_JJ to_TO the_DT results_NNS obtained_VBN in_IN the_DT present_JJ study_NN ._. In_IN
        contrast_NN ,_, the_DT Iowa_NNP Women_NNP 's_POS Health_NNP Study_NNP showed_VBD no_DT
        association_NN with_IN WHR_NNP ,_, and_CC an_DT earlier_JJR report_NN of_IN interaction_NN
        with_IN family_NN history_NN appeared_VBD to_TO have_VB attenuated_JJ with_IN time_NN [_NN
        25_CD 26_CD ]_NN ._. In_IN the_DT New_NNP York_NNP University_NNP Women_NNP 's_POS Health_NNP Study_NNP ,_,
        the_DT multivariable_JJ analysis_NN showed_VBD an_DT association_NN between_IN
        the_DT lowest_JJS quintile_NN and_CC the_DT highest_JJS quintile_NN of_IN WHR_NNP and_CC
        breast_NN cancer_NN of_IN 1_CD ._. 72_CD (_( 95_CD %_NN confidence_NN interval_NN =_SYM 1_CD ._. 0_CD -_: 3_CD ._. 1_LS )_)
        among_IN premenopausal_NN women_NNS ,_, but_CC there_EX was_VBD no_DT association_NN
        among_IN postmenopausal_NN women_NNS [_NN 27_CD ]_NN ._.
        Most_JJS case-control_JJ studies_NNS have_VBP found_VBN an_DT association_NN
        between_IN WHR_NNP and_CC the_DT risk_NN of_IN postmenopausal_NN breast_NN cancer_NN [_NN
        28_CD 29_CD 30_CD 31_CD 32_CD 33_CD 34_CD 35_CD 36_CD 37_CD ]_NN ,_, and_CC most_JJS report_NN either_CC
        null_NN or_CC weakly_RB positive_JJ association_NN with_IN premenopausal_NN
        breast_NN cancer_NN ._. In_IN the_DT present_JJ study_NN ,_, there_EX was_VBD no_DT
        statistically_RB significant_JJ association_NN between_IN breast_NN cancer_NN
        and_CC WHR_NNP for_IN premenopausal_NN women_NNS ._.
        Studies_NNS of_IN WHR_NNP and_CC the_DT risk_NN of_IN breast_NN cancer_NN are_VBP limited_VBN
        by_IN systematic_JJ bias_NN in_IN the_DT measurement_NN of_IN WHR_NNP across_IN studies_NNS
        [_NN 36_CD ]_NN ,_, which_WDT may_MD have_VB been_VBN controlled_VBN somewhat_RB in_IN this_DT
        study_NN by_IN using_VBG nurse_NN interviewers_NNS and_CC adhering_VBG to_TO the_DT World_NNP
        Health_NNP Organization_NNP MONICA_NNP guidelines_NNS [_NN 10_CD ]_NN ._. In_IN
        case-control_JJ studies_NNS like_IN the_DT present_JJ one_CD ,_, selection_NN and_CC
        recall_VB bias_NN can_MD be_VB problematic_JJ ._. While_IN we_PRP restricted_VBD our_PRP$
        analysis_NN to_TO urban_JJ dwellers_NNS ,_, finer_NN adjustment_NN based_VBN on_IN the_DT
        community_NN of_IN residence_NN or_CC the_DT restriction_NN of_IN cases_NNS to_TO only_RB
        those_DT from_IN the_DT community_NN from_IN which_WDT controls_NNS were_VBD selected_VBN
        would_MD have_VB increased_VBN the_DT validity_NN of_IN the_DT result_NN ._. The_DT
        finding_NN of_IN two_CD cases_NNS of_IN cancer_NN among_IN the_DT controls_NNS may_MD be_VB
        due_JJ to_TO chance_NN ._.
        The_DT prevalence_NN of_IN obesity_NN in_IN the_DT cases_NNS and_CC controls_NNS also_RB
        appears_VBZ higher_JJR than_IN expected_VBN but_CC this_DT may_MD be_VB consistent_JJ
        with_IN the_DT increasing_VBG rate_NN of_IN obesity_NN in_IN developing_VBG
        countries_NNS ,_, especially_RB in_IN the_DT urban_JJ areas_NNS [_NN 38_CD ]_NN ._.
        Preclinical_NNP weight_NN loss_NN is_VBZ not_RB usually_RB a_DT problem_NN in_IN breast_NN
        cancer_NN [_NN 39_CD ]_NN ,_, and_CC sub-analysis_JJ of_IN our_PRP$ data_NNS confirmed_VBD
        this_DT ._. Inclusion_NNP of_IN obesity_NN in_IN the_DT multivariate_NN analysis_NN did_VBD
        not_RB change_VB the_DT result_NN ,_, and_CC obesity_NN was_VBD not_RB a_DT significant_JJ
        predictor_NN of_IN outcome_NN in_IN multivariate_NN regression_NN analysis_NN ._.
        Other_JJ limitations_NNS of_IN this_DT study_NN include_VBP the_DT absence_NN of_IN
        information_NN about_IN breastfeeding_VBG and_CC the_DT features_NNS of_IN a_NNP
        '_POS Western_JJ lifestyle_NN '_'' such_JJ as_IN physical_JJ activity_NN ,_, diet_NN and_CC use_NN
        of_IN postmenopausal_NN hormones_NNS and_CC other_JJ medications_NNS ._.
        In_IN conclusion_NN ,_, the_DT present_JJ study_NN is_VBZ consistent_JJ with_IN
        findings_NNS in_IN other_JJ environments_NNS that_IN central_JJ adiposity_NN is_VBZ a_DT
        risk_NN factor_NN for_IN breast_NN cancer_NN in_IN postmenopausal_NN women_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        BMI_NNP =_SYM body_NN mass_NN index_NN ;_: LRT_NNP =_SYM likelihood_NN ratio_NN test_NN ;_: SHBG_NNP
        =_SYM sex_NN hormone_NN binding_JJ globulin_NN ;_: WHR_NNP =_SYM waist-hip_JJ ratio_NN ._.
      
    
  
